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Abstract: Osteoarthritis (OA) is a degenerative disorder associated with cartilage loss and is a leading
cause of disability around the world. In old age, the capacity of cartilage to regenerate is diminished.
With an aging population, the burden of OA is set to rise. Currently, there is no definitive treatment for
OA. However, cell-based therapies derived from adipose tissue are promising. A PRISMA systematic
review was conducted employing four databases (MEDLINE, EMBASE, Cochrane, Web of Science)
to identify all clinical studies that utilized adipose tissue derived mesenchymal stem cells (AMSCs)
or stromal vascular fraction (SVF) for the treatment of knee OA. Eighteen studies were included,
which met the inclusion criteria. Meta-analyses were conducted on fourteen of these studies, which
all documented WOMAC scores after the administration of AMSCs. Pooled analysis revealed that
cell-based treatments definitively improve WOMAC scores, post treatment. These improvements
increased with time. The studies in this meta-analysis have established the safety and efficacy of
both AMSC therapy and SVF therapy for knee OA in old adults and show that they reduce pain and
improve knee function in symptomatic knee OA suggesting that they may be effective therapies to
improve mobility in an aging population.
Keywords: osteoarthritis; degenerative changes; knee; adipose tissue; mesenchymal stem cells;
stromal vascular factor
1. Introduction
1.1. The Burden of Osteoarthritis
Osteoarthritis (OA) is a progressive degenerative joint disorder associated with aging.
It is a leading cause of disability around the world. In 2019, the Global Burden of Disease
Study reported that musculoskeletal disorders account for over 5% of worldwide disability
adjusted life years (DALY) [1]. The World Health Organization (WHO) estimate that
approximately 10% of all men and 18% of all women aged over 60 have OA [2]. Out of
these individuals, they estimate that 80% have limitations in movement and 25% cannot
perform major daily activities of life [2].
In addition to physical symptoms, there is evidence to suggest that OA is associated
with mental health problems as well. A longitudinal cohort study, conducted by the
Osteoarthritis Initiative, found that there was a greater risk of developing depressive
symptoms in patients with hip or knee OA than those without [3]. Another observational
study found that OA was associated with 1.27 times increase odds of suicidal ideation [4].
There is also evidence that OA increases the risk for myocardial infarction, with one
meta-analysis reporting a 1.31 times increased risk for myocardial infarction [5].
These, among many other studies have highlighted the burden OA has on the indi-
vidual. In addition to this, OA carries significant economic burden on societies across the
world. When adjusted for age, sufferers are shown to be at high risk of sick leave and
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disability pension due to knee OA. This was especially the case for those working in health
care, childcare and in cleaning [6]. In the United States, annual healthcare costs from OA
exceed $45 billion [7]. In France, annual costs from OA can be as high as €2 billion [8]. In
Spain costs may be as high as €4.738 billion annually [9]. A significant proportion of these
costs are associated with joint replacement surgeries.
Economic, societal, and individual burdens caused by OA are set to rise. The preva-
lence of OA is increasing because of an aging population and an increased incidence of
obesity. The United Nations estimates that by 2050, 1 in 6 people in the world will be over
65 years of age [10]. As such incidence rates of OA will naturally also increase. Several
projection studies have been performed in different countries. In Australia, the number of
people with OA is estimated to increase from 2.2 million in 2015, to 3.1 million by 2030 [11].
In Sweden it is estimated that from between 2012 and 2032, the percentage of people aged
over 45 with OA will rise from 26.6% to 29.5% [12]. In the United States, this number is set
to grow from 47.8 million in 2005 to 67 million by 2030 [13]. These figures show there is a
global rising prevalence of this disease. Coupled with the debilitating nature of OA, this
must be addressed before the disease overburdens healthcare systems worldwide.
There is currently no cure to prevent or slow the progression of OA. Presently, it is
first managed via conservative means through exercises, weight loss and occupational
therapy. When this is inadequate, paracetamol and non-steroidal anti-inflammatory drugs
(NSAIDs) are used for symptom control [14]. Intra articular corticosteroid injections are
then used if the aforementioned therapies do not provide relief. For end-stage OA, joint
replacement surgery (total knee arthroplasty) is the gold standard of treatment. Despite
being a highly successful operation, joint replacement surgery carries significant risk, and
nearly one in five knee replacements will not last beyond 25 years [15].
OA pathogenesis is predominantly driven by inflammatory mediators such as in-
terleukin 1 (IL-1) and tumour necrosis factor alpha (TNF-α) [16]. Both are present in the
synovial fluid of patients with OA [17,18]. IL-1 has been shown to encourage the produc-
tion of molecules such as nitric oxide, cytokines and prostaglandin E2 [19]. Furthermore,
these inflammatory molecules promote the release of matrix metalloproteinases. These
encourage the catabolism of articular cartilage [20]. This process of cartilage catabolism
and loss is associated with aging, [21] alongside the diminishing ability of cartilage to
repair itself [22]. While these mechanisms are central to cartilage depletion and eventually
OA and pain, blockade of these mediators have failed to demonstrate efficacy in clinical
trials [23,24].
1.2. Mesenchymal Stem Cells
MSCs are becoming increasingly popular in tissue engineering due to their multipotent
potential to differentiate into different lineages of mesenchymal tissue types [25]. These
include bone, fat, cartilage, tendon, and muscle. MSCs are of interest as an OA therapy due
to their immunoregulatory function and potential to repair cartilage. This is particularly
useful as OA predominantly affects individuals in old age, who have limited ability to
repair cartilage.
MSC-based therapies can result in promotion of macrophage polarization from an
M1 to M2 phenotype [20,26,27]. This enables macrophages in the cartilage to display
anti-inflammatory properties which leads to down-regulation of the inflammatory milieu
mentioned above in their role in triggering and sustaining osteoarthritic changes [28].
MSCs have also been shown to be capable of suppressing T-cell proliferation. MSCs do
not express HLA class II on their surface and only express low levels of HLA class I and
have demonstrated safety and low immunogenicity through various routes of administra-
tion [29–31]. Although laboratory studies have suggested that MSCs, both intrinsic and
transplanted may promote cancer cell activity, in-human clinical trials of transplantation
have yet to show evidence of carcinogenic effect [32,33].
The Mesenchymal and Tissue Stem Cell Committee of the International Society for
Cellular Therapy recommends a minimal criterion to define human MSCs. There are three
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elements to these standards. Firstly, MSCs must be adherent to plastic when they are
maintained in standard culture conditions. Secondly, MSCs must express the following
markers: CD105, CD73 and CD90. In addition, they must not express the following: CD45,
CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR surface molecules. Thirdly MSCs
must be able to differentiate into the following cell types in vitro: osteoblasts, adipocytes
and chondroblasts [34].
MSCs can be derived from a variety of locations including skeletal muscle, syn-
ovium [35,36] and periosteum [37,38]. However, the most popular cell sources for MSC
harvest, are bone marrow [39–42] and adipose tissue [43,44]. MSCs were first isolated
from bone marrow before any other source [45,46] and bone marrow derived MSCs remain
one of the top choices for MSCs due to their high cell-yield and proliferative capacity
in vitro [47]. However, despite its advantages, extraction of bone marrow to acquire MSCs
for autologous use is a highly invasive and painful procedure that can cause long term pain
at the donor site. Thus, such a procedure is not always ideal. Hence, other sources of MSCs
have been sought out, the most popular being adipose tissue derived MSCs. These are
accessible as a surgical waste tissue and are associated with lower donor site morbidity than
bone marrow [48]. The low rejection rates coupled with the anti-inflammatory properties
of MSCs makes them an appealing therapeutic solution for OA.
1.3. Adipose Tissue Derived MSCs
The most common harvest location for Adipose tissue derived MSCs (AMSCs) is the
abdomen due to the high tissue fat content. The harvesting process by which AMSCs are
collected have been described extensively in the past [44–50].
AMSCs have a greater regenerative profile than bone marrow derived MSCs [51].
AMSCs were also found to promote greater neovascularisation, display greater resistance
to hypoxia induced apoptosis and higher telomerase activity [52]. Unlike bone marrow
derived MSCs, which lose differentiation capacity with age, AMSCs do not [53]. AM-
SCs maintain their chondrogenic potential and their expansion properties [54]. This is
very important to consider in MSC therapies targeted for OA, since these are directed at
older patients.
AMSCs have been found to have greater anti-inflammatory properties compared to
bone marrow derived MSCs and produce much higher levels of IL-1 receptor antagonist
and tissue protective protein tumour-necrosis factor stimulated gene-6 (TSG-6) [55]. When
assessed in their role for OA, AMSCs were able to adapt the environment and exerted
anti-inflammatory effects on chondrocytes and synoviocytes via prostaglandin E2 [56]. The
AMSCs caused polarization of Mo non-polarized macrophages and mature dendritic cells,
towards anti-inflammatory and phagocytic phenotypes [57].
Adipose tissue derived stem cells can also be derived from the stromal vascular
fraction (SVF) which has the advantage of greater ease of harvest. However, these cells are
not plated to select for cells which are plastic adherent [58,59]. As such, cells from the SVF
cannot strictly be considered MSCs according to the Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular Therapy criteria [34].
The aim of this systematic review and meta-analysis was to determine the effectiveness
of AMSCs and SVF for the use of treatment in osteoarthritis.
2. Materials and Methods
2.1. Database and Inclusion Criteria
A systematic review was conducted, based on the guidelines outlined in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [60]. Using
the PICOS model, (patient, intervention, control, outcome, study), inclusion and exclusion
criteria were created.
A comprehensive literature search was conducted using four databases: Medline
(1946 to 4 June 2020), EMBASE (1974 to 29 June 2020), Cochrane library (1946 to June 2020),
and Web of Science (1900 to 2020).
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The following was used as inclusion criteria for all studies screened:
1. Any studies which investigated use of AMSCs on humans for the treatment of knee
joint osteoarthritis
2. Any study that included the use of stromal vascular fraction (SVF) or microfragmented
adipose tissue
3. Any study which was clinical in nature
Consequently, the following was used as exclusion criteria for all studies screened.
1. Any study not conducted on human
2. Studies which investigated use of MSCs which were not of adipose origin
3. Any case studies and reviews
4. Studies in which the data sets were either incomplete or inaccessible such as confer-
ence abstracts and ongoing randomised controlled trials (RCTs)
A search strategy was created, on the basis of the Cochrane Highly Sensitive Search
Strategy. This included but was not limited to the following terms: ‘mesenchymal’, or
‘stem cell’ and ‘osteoarthritis, knee’ and ‘adipose’. Full search strings can be found in the
Appendix A. Restrictions were applied to the search to only include studies conducted on
humans and in the English language. Study selection was carried out by two reviewers
independently. The titles of the articles were reviewed for relevance. Abstracts were
then screened to check if they met inclusion criteria. Full-text manuscripts were then
retrieved and analysed. A manual search was also performed on associated review articles
to identify any articles that could have been missed by the search. The combined results of
the comprehensive search strategy are shown in Figure 1.
2.2. Quality Assessment
Each study was critically appraised to ensure relevance. Studies were appraised
by two independent reviewers using either the Risk of Bias in Nonrandomised Studies
1 (ROBINS-1) or the Risk of Bias 2 (RoB2) for randomised studies tools. Upon completion
of the appraisal, data was stratified according to the tools used and was collated into
tables (Supplementary Tables S1 and S2). Any uncertainty was solved through discussion
between the reviewers.
2.3. Statistical Analysis
Pre and post treatment Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) scores were extracted from each study for each of the follow-up times.
Percentage changes in these scores were then calculated for each follow-up time. Forest
plots were created for each of the follow-up time periods. A summary forest plot was
created to determine the overall statistical significance of treatment on WOMAC scores. We
sought to elucidate whether the pooled effect of treatment resulted in minimum clinically
important differences in WOMAC scores, which has been defined as 12, [61] to this end,
we do not compare this against the various control groups used across the studies. All
statistical analysis was conducted on R software through the ‘metafor’ package. The I2
test was used to test for heterogeneity. To account for heterogeneity (all-cause) between
studies, assuming effects assuming that effects between studies are either similar or not,
Fixed effect models were used for analyses with I2 < 25%. Random effect models were
used for analyses with I2 > 25%. All WOMAC percentage changes were calculated with a
95% confidence interval.
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Figure 1. Overview of the screening and selection process of studies for the systematic review.
3. Results
The search conducted on Medline (1946 to 4 June 2020), EMBASE (1974 to 29 June 2020),
Cochrane library (1946 to June 2020), and Web of Science (1900 to 2020) included 117 po-
tentially relevant articles after title screening, and 94 studies were excluded after abstract
screening as these were non-human, preclinical studies or did not assess the treatment
of interest. After full textual analysis five studies were removed as these did not in-
clude quantitative treatment outcomes relevant to our study, only eighteen studies were
then included in this review. One of the 18 studies was a two-year follow-up of another
included study [62]. The original study was a prospective cohort study which investi-
ga ed he effects of three different AMSC dose injections [63]. Out of the studies, 16 were
prospective [43,49,62–73] and two were retrospective [74,75]. Only five were randomised
controlled trials [48,49,64,69–72]. The general characteristics of each AMSC study can be
seen in Table 1. All studies investigated autologous treatments. Characteristics for SVF
studies can be found in Table 2. Cellular characteristics for AMSC studies and SVF studies
can be found in Tables 3 and 4, respectively. Outcomes measured, and complications
documented have been collated for each study in Table 5. The overall bias determined
in all studies included in this systematic review were found to be low, indicating high
quality studies.
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Table 1. Study characteristics for AMSC studies, n = 11.




No. of Patients in
Treatment Group
(Gender)




Lee et al. (2019) [64] Prospective double blinded RCT AMSC at 1 dose, control 12 (3M, 9F) 12 (3M, 9F) 62.7 Knee II–IV (K-L)
Freitag et al. (2019) [76] Prospective non blinded RCT AMSC at 2 doses, control 10 (5M, 5F)
10 (7M, 3F) for 1
injection.
10 (4M, 6F) for 2
injections
53.6 Knee II–III (K-L)
Song et al. (2018) [48] Prospective double blinded RCT AMSC at 3 doses, no control N/A 18 (4M, 14F) 54.8 Knee II–III (K-L)
Roato et al. (2019) [73] Prospective single arm study AMSC at 1 dose, no control N/A 20 (9M, 11F) 59.6 Knee I–III (K-L)
Hudetz et al. (2019) [63] Prospective non-randomised trial AMSC injection, no control N/A 20 (15M, 5F) Notspecified Knee III–IV (K-L)
Spasovski et al. (2018) [65] Prospective single arm study AMSC at 1 dose, no control N/A 9 (3M, 6F) 63 Knee B-D (IKDC)
Jo et al. (2017) [62] Prospective cohort study AMSC at 3 doses, no control N/A 18 (3M, 15F) 61.8 Knee III–IV (K-L)
Bansal et al. (2017) [77] Prospective interventional AMSC injection, no control N/A 10 (6M, 4F) 58.4 Knee I–II (BS)
Pers et al. (2016) [72] Prospective single arm study AMSC at 3 doses, no control N/A 18 (8M, 10F) 64.6 Knee III–IV (K-L)
Jo et al. (2014) [63] Prospective cohort study AMSC at 3 doses, no control N/A 18 (3M, 15F) 61.8 Knee III–IV (K-L)
Yokota et al. (2019) [75] Retrospective cohort study AMSC vs SVF, no control N/A 80 (16M, 64F) 71.4 Knee II–IV (K-L)
AMSC = Adipose Tissue Derived Mesenchymal Stem Cell, F = Female, IKDC = International Knee Documentation Committee, K-L = Kellgren-Lawrence, M= Male, N/A = Not Applicable, OA = Osteoarthritis,
RCT = Randomised Controlled Trial.
Table 2. Study characteristics for SVF studies, n = 7.
Authors Type of Study Treatment vs. Control










Garza et al. (2020) [69] Prospective double blinded RCT High dose SVF vs low doseSVF vs placebo 13 (6M, 7F)
13 (4M, 9F) for
low dose SVF.
13 (7M, 6F) for
high dose SVF.
59.0 Knee II–III (K-L)
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Table 2. Cont.
Authors Type of Study Treatment vs. Control










Hong et al. (2019) [70] Prospective RCT
One knee with SVF and the
other with hyaluronic
acid placebo
16 (3M, 13F) 16 (3M, 13F) Notspecified Knee II-III (K-L)





15 (3M, 12F) 18 (5M, 13F) 58.64 Knee II–III (K-L)
Yokota et al. (2017) [68] Prospective uncontrolled Injection of SVF, no control N/A 13 (2M, 11F) 74.5 Knee III–IV (K-L)
Nguyen et al. (2016) [67] Prospective unblinded,non-randomised trial
Arthroscopic fracture vs
arthroscopic fracture and
injection of SVF and PRP.
15 (3M, 12F) 15 (3M, 12F) 58.4 Knee II–III (K-L)
Koh et al. (2013) [66] Prospective cohort study SVF at 1 dose with PRP,no control N/A 18 (6M, 12F) 54.6 Knee III–IV (K-L)
Panni et al. (2019) [74] Retrospective single arm study





N/A 52 (22M, 30F) 57.3 Knee 0–II (K-L)
BS = Brandt Radiographic Grading Scale for Osteoarthritis, F = Female, K-L = Kellgren-Lawrence, M= Male, N/A = Not Applicable, OA = Osteoarthritis, RCT = Randomised Controlled Trial, SVF = Stromal
Vascular Fraction.
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Table 3. Cellular characteristics for AMSC studies, n = 11.
Authors Number of CellsUsed/Multiple Injections Method of Delivery of Cells MSC Pre-Treatment
Follow-Up






Lee et al. (2019) [64] 1 × 108 cells Intra articular injection under USSguidance into unspecified joint space
Adipose tissues were treated
with collagenase I and were
centrifuged to obtain a pellet
which was resuspended in
culture media. The cells were
cultured for up to 5 days in
media until confluent and were





for CD31, CD34, CD45
Freitag et al. (2019) [49] 100 × 10
6 cells, single and
double injection
Intra articular injection under USS




MSCs were cultured under
hypoxic conditions with
standard growth media until
80% confluency and was
expanded to passage 2.
52 Abdomen Liposuction
AMSCs were positive




Song et al. (2018) [48] 1 × 10
7, 2 × 107 and 5 × 107
cells, three injections
Intra articular injection under USS
guidance into unspecified location in
joint space
Lipoaspirated suspensions were
digested and centrifuged, then
cells were culture-expanded to
passage 4.
96 Not specified Liposuction
AMSCs were positive
for CD29, CD49d, CD70,
CD90 and were
negative for actin, CD13,
CD34, CD45, HLA-DR
Roato et al. (2019) [73] Not specified
Intra articular injection under
arthroscopic guidance into chondral
defect site
Lipoaspirate was treated with
Collagenase. The resulting cell
pellet was then resuspended
into culture media and counted.
78 Abdomen Liposuction
AMSCs were positive




Hudetz et al. (2019) [71] Unspecified Intra articular injection intounspecified location in joint space
Samples were digested with
collagenase and samples were
filtered through a 100 µm cell
strainer and centrifuged. The




for CD70, CD90, CD105,
CD146.
AMSCs were negative
for CD31, CD34, CD45.
Spasovski et al. (2018) [65] 0.5–1 × 107 cells Intra articular injection intounspecified location in joint space
MSCs were digested using
collagenase, expanded in
standard culture media and




for CD73, CD90, CD105.
AMSCs were negative
for CD34, CD45
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Table 3. Cont.
Authors Number of CellsUsed/Multiple Injections Method of Delivery of Cells MSC Pre-Treatment
Follow-Up






Jo et al. (2017) [62] 1 × 10
7, 5 × 107 and
1 × 108 cells
Intra articular injection under
arthroscopic guidance into
unspecified location in joint space
Aspirated tissues were digested
with collagenase I. Cells were
cultured for 4-5 days until
confluent. All AMSCs used in






for CD14, CD34, CD45
Bansal et al. (2017) [77] 1 × 106 cells Intra articular injection intounspecified location in joint space
The adipose tissues was filtered
and centrifuged. The cell pellet
was re-suspended in culture
medium and the media was
changed every 3-4 days until the
cells achieved 90% confluency.
96 Abdomen Liposuction
AMSCs were positive




Pers et al. (2016) [72] 2 × 10
6, 10 × 106 and
50 × 106 cells
Intra articular injection under USS
guidance into unspecified location in
joint space
Adipose tissue was digested
with collagenase solution and
plated in culture medium. Cells
were passaged and then
cultured in CCM for 14 days
with media changes every
3–4 days until confluence.
26 Abdomen Liposuction
AMSCs were positive
for CD73, CD90, CD105,
IgG1
AMSCs were negative
for CD31, CD34, CD45
Jo et al. (2014) [63] 1 × 10
7, 5 × 107 and
1 × 108 cells
Intra articular injection under
arthroscopic guidance into
unspecified location in joint space
Aspirated tissues were digested
with collagenase and cells were
resuspended in media until
confluent. AMSCs used were





for CD31, CD34, CD45
Nakamura et al. (2019) [75] 12.75 × 10
6 cells, unknown
for SVF
Intra articular injection into
unspecified location in joint space
The collected aspirate was
digested with collagenase. Cells
were cultured in medium that
was replaced every 3 days
thereafter. When cells reached
80% confluency they were
passaged up to four times.
SVF cells were produced
without culture in a sterile
single-use functionally-closed
system, requiring approximately
2–2.5 h from lipoaspirate.
26 Abdomen Liposuction Not specified
AMSC = Adipose Tissue Derived Mesenchymal Stem Cell, BSA = Bovine Serum Albumin, CDU = Collagen Digestion Units, DPBS = Dulbecco’s Phosphate-Buffered Saline, DMEM = Dulbecco’s Modified Eagle
Medium, EDTA = Ethylenediaminetetraacetic acid, FBS = Foetal Bovine Serum, MSC = Mesenchymal Stem Cell, PBS = Phosphate-Buffered Saline, SVF = Stromal Vascular fraction, USS = Ultrasound.
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Garza et al. (2020) [69] 3.0 × 10
7, 1.5 × 107,
0 cells
Intra articular injection under
USS guidance into unspecified
joint space
SVF from dissociated tissue
was centrifuged and the SVF
cell pellet was extracted,
resuspended for injection.
48 Abdomen Liposuction Not specified
Hong et al. (2019) [70] 7.45 × 106 cells




The SVF from the
lipoaspirate was isolated by
means of collagenase
digestion. The SVF was then
washed twice with PBS to
remove collagenase.
48 Abdomen Liposuction Not specified
Tran et al. (2019) [78] 9–12 × 107 cells
Intra articular injection under
arthroscopic guidance into
chondral defect site
The SVF from the
lipoaspirate was isolated
through collagenase
treatment. The SVF was then
diluted with normal saline
0.9% to obtain 6 mL of
solution containing
90–120 million cells to
administer via injection.
96 Abdomen Liposuction Not specified
Yokota et al. (2017) [68]
Unknown, however
estimated to be
3 × 107 cells
Intra articular injection into
unspecified location in
joint space
Autologous SVF cells were





4 Abdomen Liposuction Not specified
Nguyen et al. (2016) [67] 1 × 107 cells
Intra articular injection under
arthroscopic guidance into
chondral defect site
The adipose tissue was
digested using collagenase
and centrifuged, the pellet
was suspended in PBS for
cell counting
before injection.
72 Abdomen Liposuction Not specified

















Koh et al. (2013) [66] 1.18 × 106 cells
Intra articular injection into
unspecified location in
joint space
SVF was derived from fat
pad tissue and mixed with








Panni et al. (2019) [74] Not specified




The harvested fat was
processed with the




61.2 Abdomen Liposuction Not specified
AMSC = Adipose Tissue Derived Mesenchymal Stem Cell, CDU = Collagen Digestion Units, DPBS = Dulbecco’s Phosphate-Buffered Saline, DMEM = Dulbecco’s Modified Eagle Medium, FBS = Foetal Bovine
Serum, MSC = Mesenchymal Stem Cell, PBS = Phosphate-Buffered Saline, SVF = Stromal Vascular fraction, USS = Ultrasound.
Table 5. Outcomes and complications, n = 18.
Authors Outcome Measures Pre-Treatment WOMACScores Post Treatment WOMAC Scores Conclusions Based on Outcomes Adverse Events Nature of Complications
Lee et al. (2019) [64]
WOMAC, VAS, KOOS,
ROM, K-L, Joint space
width of medial and lateral
compartment and
HKA angle
Baseline WOMAC score was
60.0 (±17.0 SD)
At 6 months post procedure
WOMAC scores were 26.7
(±13.3 SD)
Single injection of AD-MSCs led to a
55% reduction in the WOMAC total
score, 59%
in the pain score, 54% in the stiffness
score, and 54% in the physical function
score at 6 months.
Significant improvements in the VAS,
KOOS, ROM scores were also seen.
K-L grade, joint space width of medial
and lateral compartment, and HKA
angle did not change significantly over
6 months in either groups.
No evidence of significant cartilage
regeneration in MRI at 6 months after
the injection.
8AEs 6 cases of arthralgia and 2 cases of jointswelling after the procedure.
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Table 5. Cont.
Authors Outcome Measures Pre-Treatment WOMACScores Post Treatment WOMAC Scores Conclusions Based on Outcomes Adverse Events Nature of Complications
Freitag et al. (2019) [49] NPRS-11, WOMAC,KOOS, MOAKS
WOMAC scores were 59.6
(±17.9 SD) for the one injection
group and 54.4 (±18.2 SD) for
the two-injection group
WOMAC scores were 84
(±9.4 SD) for the one injection
group and 87.3 (±8 SD) for the
two-injection group at 12 months.
NPRS-11 scores were greater when
compared with baseline (< 0.05)
throughout all time points in all
treatment groups. There was no
difference however between treatment
groups. KOOS and WOMAC
improved in all subscales during
follow-up to 12 months. Two-thirds of
the control group showed cartilage
loss. 30% of the one-injection group
had further cartilage loss, 50% had
progression of osteophyte formation at
12 months. 89% in the two-injection
group had either no progression or
improvement in cartilage loss.
7 AEs and 1 SAE in
the one
injection group.
8AEs and 1 SAE in the
first injection of the
two-injection group.
10 AEs in the second
injection in the
two-injection group.
Mild AEs: minor discomfort, bruising
and/or swelling after the injection. SAEs
were classified as pain and sweeling for
4 weeks after injection which impacted
the daily activities of life for the patient.
Song et al. (2018) [48] WOMAC, NPRS-11, SF-36, WOMAC scores were 34.75(±17.05 SD) at baseline
WOMAC scores were 25.94
(±16.09 SD), 20.38 (±19.89 SD),
22.77 (±22.72 SD), 15.00
(±11.36 SD) and 12.44 (±8.99 SD)
in the 12th, 24th, 48th, 72nd and
96th week.
WOMAC scores improved with time
leading up to follow-up in all groups.
Significant improvements in the
NPRS-11 scores in the low- and
high-dose groups were first observed
at three months following treatment.
A statistically significant reduction in
SF-36 scores were only found in the
12th and 96th week of follow-up
The volume of knee cartilage increased
over the course of follow-up. This was
more apparent in the high-dose group
8 AEs in the low dose
group (66.67%). 7 AEs
in the middle dose
group (58.33%). 6 AEs
in the high dose
group (50%).
No SAEs or deaths. All complications
were AEs. These were most commonly
transient pain and swelling of joints,
which were mild to moderate and were
spontaneously relieved within 7 days
without special treatment. One patient
experienced mild oedema and cramps of
bilateral lower extremities, which were
relieved in 21 days without treatment
and not related to the MSC treatment.
Roato et al. (2019) [73] WOMAC, VAS, K-L
WOMAC score was 45.91
(±2.8) pre procedure.
(NO SE OR SD GIVEN)
WOMAC scores were 27.47
(±3.02), 15.84 (±2.5) and 12.97
(±2.3) at 3 months, 6 months and
18 months post procedure. (NO
SE OR SD GIVEN)
Significant improvement of VAS and
WOMAC scores, with a significant
pain reduction and increased mobility
at 3, 6, and 12 months follow-up.
No increase in the thickness of
cartilage at 18 months.
1 SAE Swelling persisted two monthsafter surgery
Hudetz et al. (2019) [71] KOOS, WOMAC, VAS WOMAC baseline score was55.38 (±18.8 SD)
WOMAC scores after 12 months
was 32.25 (±14.6 SD)
All scores significantly improved
after treatment. 0 AEs or SAEs N/A
Spasovski et al. (2018) [65] KSS, HSS, Lysholm score,VAS, MOCART N/A N/A
All outcomes significantly improved
at 3 and 6 months. However, there
was no further improvement beyond
12 or 18 months after treatment.
N/A N/A
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Jo et al. (2017) [62]
WOMAC, VAS, KSS,
KOOS, K-L, Joint space
width of the medial
compartment, mechanical
axis with weight bearing
line, and anatomical axis
WOMAC scores were 43.3
(±12.7 SE) for the low dose
group, 69.0 (±5.9 SE) for the
mid dose group and 54.2 (±5.2
SE) for the high dose group.
WOMAC scores were 25.3
(±19.5 SE), 14.7 ± (12.7 SE) and
17.0 (±9.8 SE) at 6 months, 1 year
and 2 years respectively for the
low dose group.
WOMAC scores were 48.5
(±9.5 SE), 13.1 (±10.0 SE) and 25.1
(±11.0 SE) at 6 months, 1 year and
2 years respectively for the
middle dose group.
WOMAC scores were 32.8
(±6.3 SE), 16.0 (±4.4 SE) and 19.0
(±5.5 SE) at 6 months, 1 year and
2 years respectively for the high
dose group.
The WOMAC, VAS and KSS scores
improved in the high-dose group at
6 months and 1 year. Non-significant
trends in the low and middle dose
groups. Significant improvement in
KSS scores in the low dose groups up
to one year. The sports subscore of the
KOOS improved until 2 years for the
high-dose group. No statistically
significant improvements were found
in the quality-of-life subscore of the
KOOS for any of the dose groups.
None None
Bansal et al. (2017) [77] WOMAC, 6MWD,cartilage thickness
WOMAC score was 64 at
baseline (NO SE OR SD
GIVEN)
WOMAC scores were 52, 46, 42,
38 and 41 at 3 months, 6 months,
12 months, 18 months and 24
months respectively. (NO SE OR
SD GIVEN)
Significant changes in the WOMAC
and 6MWD scores were noted in both
the subsets and the total after 2 years
as compared to the baseline. MRI
evaluation demonstrated that cartilage
thickness improved.
1 AE Pain and swelling which resolved.
Pers et al. (2016) [72] WOMAC, VAS, PGA, SAS,KOOS, OARSI, SF-36
WOMAC scores were 63.2
(±4.1 SD) for the low dose
group, 65.5 (±8.1 SD) for the
mid dose group and 65.2
(±2.3 SD) for the high
dose group.
WOMAC scores were 24.6
(±8.6 SD), 22.0 (±8.5 SD) and 30.1
(±8.9 SD) at 1 week, 3 months
and 6 months respectively for the
low dose group.
WOMAC scores were 45.8
(±9.1 SD), 52.8 (±9.6 SD) and 42.6
(±9.1 SD) at 1 week, 3 months
and 6 months respectively for the
middle dose group.
WOMAC scores were 61.1
(±15.3 SD), 38.4 (±16.0 SD) and
42.6 (±16.0 SD) at 1 week,
3 months and 6 months
respectively for the high
dose group.
Statistically significant improvements
in WOMAC, VAS, KOOS and SAS
scores were only found in the low
dose group at 1 week, 3 months and
6 months.
No improvements in the SF-36 in
any groups.
1 SAE and 5 AEs.
The SAE was unstable angina pectoris
without increased cardiac markers,
which was reported in 1 patient
3 months after
ASC injection. The patient’s risk factors
included hypertension and
hyperlipidemia.
Five AEs reported by four patients.
There was slight knee pain/joint effusion
occurred during the first week after ASC
injection that resolved with nonsteroidal
anti-inflammatory drugs in three
patients and spontaneously in
one patient.
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Jo et al. (2014) [63]
WOMAC, VAS, KSS, K-L,
Joint space width of the
medial compartment,
mechanical axis with
weight bearing line, and
anatomical axis, ICRS
WOMAC scores were 43.3
(±12.7 SE) for the low dose
group, 69.0 (±5.9 SE) for the
mid dose group and 54.2
(±5.2 SE) for the high
dose group.
WOMAC scores were 44.0
(±4.4 SE), 30.0 (±12.0 SE), 38.7
(±24.7 SE) and 25.3 (±19.5 SE) at
1, 2, 3 and 6 months respectively
for the low dose group.
WOMAC scores were 72.3
(±4.3 SE), 51.3 (±6.5 SE), 51.3
(±6.7 SE) and 48.5 (±11.0 SE) at 1,
2, 3 and 6 months respectively for
the mid dose group.
WOMAC scores were 45.5
(±4.5 SE), 40.1 (±6.0 SE), 37.0
(±6.8 SE) and 32.8 (±6.3 SE) at 1,
2, 3 and 6 months respectively for
the high dose group.
Significant improvement of the
WOMAC and VAS at 6 months
compared with baseline in the
high-dose groups. This was not seen
in the other treatment groups.
Knee subsection of KSS significantly
increased in the low-dose and the
high-dose groups, but improvements
in the function subsection of seen in
the low-dose group only.
Other parameters did not change
significantly at 6 months in
any groups.
The ICRS grade of the cartilage defect
significantly improved in the medial
femoral and tibial condyle in the
high-dose group at second-look
arthroscopy. No significant change
was found in the lateral parts of
the joint.
1 AE and 1 SAE in the
low dose group
(66.6%). 2 AEs in the
mid dose group
(66.6%). 5 AEs in the
high dose group
(41.66%).
In the low dose group, the AE was an
individual case of nasopharyngitis, and
the SAE was a urinary calculus.
In the mid dose group AEs were
individual cases of nasopharyngitis,
arthralgia and chest pain.
In the high dose group AEs were
individual cases of nasopharyngitis,
arthralgia, back pain, cough and
hypertriglyceridemia.
Yokota et al. (2019) [75] KOOS, VAS, OARSI, K-L N/A N/A
Change in KOOS symptoms occurred
earlier in the AMSC group than the
SVF group, with significant
improvement detected at 3 months
follow-up.
The extent of VAS improvement after
injection was greatest in patients with
mildest. Patients in the AMSC group
had a greater improvement in VAS
than patients in the SVF group,
regardless of the extent of OA
at baseline.
The proportion of patients who
responded to treatment as determined
by the OMERACT-OARSI responder
criteria was greater in the AMSC
group than the SVF.
3AEs in the ASC
group and 26 AEs in
the SVF group.
In the ASC group, there was 1 case of
joint swelling after the injection and
2 cases of abdominal induration after
harvest. These were all self-limiting.
In the SVF group, there were 3 cases of
joint swelling after the injection. There
were 6 cases of abdominal pain, 5 cases
of abdominal swelling and 12 cases of
abdominal induration after harvest.
These were all self-limiting.
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Garza et al. (2020) [69] WOMAC, OS
Baseline WOMAC scores were
49.3 for the placebo group, 56.2
for the low dose group and 47.1
for the high dose group (THIS
WAS THE MEAN. NO SE OR
SD WAS GIVEN) Median was
49.8 (37.4–57.0), 51.6 (46.3–62.3)
and 49.8 (35.6–55.2) for the
placebo, low dose and high
dose groups.
WOMAC scores for the placebo
was 26.0, 22.9, 37.2 and 41.9 at 6




30.2 (21.4–55.2), 41.0 (19.5–55.2).
WOMAC scores for the low dose
group was 24.8, 19.7, 23.7 and 21.8
at 6 weeks, 3 months, 6 months
and 1 year respectively.
Median values were 20.0
(10.7–37.4), 14.0 (5.3–35.6), 26.7
(8.9–32.0), 12.5 (7.1–35.6)
WOMAC scores for the high dose
group was 25.7, 26.5, 20.0 and 13.2
at 6 weeks, 3 months, 6 months
and 1 year respectively.
Median values were 27.0
(14.2–36.0), 27.0 (10.7–34.7), 8.9
(3.6–32.0), 3.6 (0.0–26.7)
All groups displayed a reduction in
total WOMAC score from baseline at
6 month follow-up.
All treated groups continued to
demonstrate lower total WOMAC
scores 1 year after injection as
compared with baseline scores and
sixth month scores. There was no
change in cartilage thickness detected
at six month follow-up.
0 AEs or SAEs N/A
Hong et al. (2019) [70] VAS, WOMAC, ROM,WORMS, MOCART
Baseline WOMAC pain score
was 9.50 (±3.92 SD) for the
control group and was 9.44
(±3.90 SD) for the
treatment group.
Baseline WOMAC stiffness
score was 3.00 (±1.55 SD) for
the control group and was 3.31
(±1.82 SD) for the
treatment group.
WOMAC pain scores were 8.94
(±4.98 SD), 11.56 (±6.84 SD),
12.88 (±5.73 SD) and 15.19
(±4.29 SD) at 1 month, 3 months,
6 months and 12 months
respectively for the control group.
WOMAC stiffness scores were
4.38 (±2.22 SD), 4.94 (±2.49 SD),
5.44 (±2.56 SD) and 5.69
(±2.57 SD) at 1 month, 3 months,
6 months and 12 months
respectively for the control group.
WOMAC pain scores were 6.25
(±3.02 SD), 2.13 (±3.52 SD), 1.5
(±3.84 SD) and 1.44 (±4.77 SD) at
1 month, 3 months, 6 months and
12 months respectively for the
treatment group.
WOMAC stiffness scores were
1.75 (±1.59 SD), 1.12 (±1.80 SD),
0.81 (±1.59 SD) and 1.06
(±2.11 SD) at 1 month, 3 months,
6 months and 12 months
respectively for the
treatment group.
In the treated group, all scores
including VAS, WOMAC pain,
WOMAC stiffness, and knee ROM was
founded to be significantly improved
at one, three, six, and 12-months
follow-up as compared with baseline
scores within the treated groups and
against control groups. Both WORMS
and MOCART MRI scores showed a
statistically significant improvement
in the treatment group, while a
deterioration in the control group.
10 AEs
4 AEs relating to abdominal pain after
harvest which resolved after 1 week.
6 cases of pain and swelling in both
knees after surgery. These all resolved
after 2 weeks with analgesia.
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Tran et al. (2019) [78] VAS, WOMAC, OS, BME,K-L
WOMAC scores were 52.0
(±18.26 SD) and 42.64
(±12.51 SD) at baseline for
patients with KL OA grade 2
and 3 respectively.
For KL OA grade 2 patients,
WOMAC scores were 24.25
(±19.77 SD) and 18.25
(±20.07 SD) at 12 and 24 months
respectively.
For KL OA grade 3 patients,
WOMAC scores were 18.21
(±8.20 SD) and 9.00 (±8.46 SD) at
12 and 24 months respectively.
No significant difference was found
between the VAS scores of the
treatment and placebo groups at
12 months.A decreasing trend in the
VAS and WOMAC scores of the
treatment group was observed up to
24 months compared to controls.
Between 12 and 24 months, the VAS
scores increased in the placebo group.
MRI results showed that after
24 months of treatment, bone marrow
oedema was decreased in both the
placebo and the SVF treatment groups,
the latter demonstrated a greater effect.
The Outbridge score also decreased in
the SVF-treated group.
N/A N/A
Yokota et al. (2017) [68] JKOM, WOMAC, VAS Baseline WOMAC scores were49.6 (±20.4 SD)
WOMAC scores were 43.0
(±17.4 SD) and 36.5 (±21.9 SD) at
1 month and 6 months after
treatment respectively
JKOM, WOMAC, and VAS scores
were significantly improved compared
to baseline one month following
treatment. This effect was also
observed at the six-month visit. JKOM
scores improved by an average of 35%
over baseline compared to a 32%
improvement in WOMAC, and 40%
for VAS.
26 AEs
All patients experienced pain and
swelling at the fat harvest and injection
sites. These however resolved after a few
days with analgesia.
Nguyen et al. (2016) [67] WOMAC, Lysholm score,VAS, OS, BME, JMA,
WOMAC scores for the placebo
group was 47.27 (±17.13 SD).
WOMAC scores for the
treatment group was 42.87
(±16.29 SD)
WOMAC scores for the placebo
group was 23.27 (±15.61 SD) and
25.60 (±19.69 SD) at 6 and
12 months respectively.
WOMAC scores for the treatment
group were 19.27 (±14.87 SD) and
17.33 (±14.91 SD) at 6 and
12 months respectively.
WOMAC scores significantly
decreased compared with baseline
scores at 6 and 12 months.WOMAC
scores between the treatment and
placebo groups were not significantly
different at 12 months, but a
significant difference was seen at
18 months. VAS and Lysholm scores
improved in the treatment group
compared to pre treatment scores at all
follow-up timepoints.
0 AEs or SAEs N/A
Koh et al. (2013) [66] WOMAC, lysholm score,VAS, WORMS
Baseline WOMAC score was
49.9 (±12.6 SD)
After final follow-up post
procedure WOMAC scores were
30.3 (±9.2 SD)
WOMAC scores decreased in the
treatment group over the follow-up
period. Greater changes in WOMAC
score were seen in subjects injected
with greater cell numbers.
Lysholm and VAS scores also
significantly improved over the
follow-up period. Significant
reduction was observed in the
WORMS cartilage subscore.
1 AE Notable pain and swelling after injectionfor 2 weeks. This was self-limiting.
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Panni et al. (2019) [74] IKS, VAS, N/A N/A
96.2% of treated subjects reported
improvements in knee function
and/or pain.
A subset (62%) achieved complete or
near-complete function recovery
and/or pain relief. Two (3.9%) patients
reported slight reduction of the pain.
3AEs Transient haematoma after harvest
6MWD = 6 Minute Walk Distance, BMA = Bone Marrow Oedema, HKA = hip-knee-ankle, HSS = Hospital for Special Surgery Knee score, ICRS = International Cartilage Repair Society, IKS = International
Knee Society, JKOM = Japanese Knee Osteoarthritis Measure, JMA = Joint Motion Amplitude, KOOS = Knee Injury and Osteoarthritis Outcome Score, K-L = Kellgren-Lawrence, KSS = Knee Society Score,
MOAKs = MRI Osteoarthritis Knee Score, MOCART = 2D Magnetic Resonance Observation of Cartilage Repair Tissue, NPRS = Numeric Pain Rating Scale, OARSI = Osteoarthritis Research Society International,
OS = Outerbridge Classification System, PGA = Patient Global Assessment score, ROM = range of motion, SAS = Short Arthritis Assessment scale, SF-36 = Short Form-36, WOMAC = Western Ontario and
McMaster Universities Osteoarthritis Index, WORMS = Whole-Organ MRI Score, VAS = visual analogue scale.
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Forest plots were created, according to the follow-up time periods utilised, to anal-
yse changes in WOMAC scores post AMSC and SVF treatment (Figure 2) in the treat-
ment group.




Figure 2. Forest plots showing percentage changes in WOMAC score less than one month after treatment (a), approxi-
mately two months after treatment (b), three months after treatment (c), six months after treatment (d), twelve months 
after treatment (e), eighteen months after treatment (f) and twenty-four months after treatment (g) (1-inj = 1 injection, 2-
inj = 2 injections, 3-inj = 3 injections, CI = confidence intervals, df = degrees of freedom, HD = high dose, LD = low dose, 
MD = middle dose, N = number, RE = random effects, Tx = treatment group). 
Figure 2. Forest plots showing percentage changes in WOMAC score less than one month after treatment (a), approxi-
mately two months after treatment (b), three months after treatment (c), six months after treatment (d), twelve months
after treatment (e), eighteen months after treatment (f) and twenty-four months after treatment (g) (1-inj = 1 injection,
2-inj = 2 injections, 3-inj = 3 injections, CI = confidence intervals, df = degrees of freedom, HD = high dose, LD = low dose,
MD = middle dose, N = number, RE = random effects, Tx = treatment group).
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Figure 2a shows all four studies which documented WOMAC scores less than 1 month
after treatment [63,68,70,72,78]. There was a statistically significant improvement in
WOMAC scores in the individual arm studies, and in the high dose groups of the other
studies. The pooled analysis showed a −20.24% change [95% CI −35.70, −4.78] suggesting
that use of AMSCs and SVF resulted in a statistically significant improvement in WOMAC
scores less than a month after treatment [Q = 232.46, p < 0.0001]. Figure 2b–g show all
studies which evaluated WOMAC scores at approximately two months, three months,
six months, twelve months, eighteen months and twenty-four months after treatment,
respectively [48,49,62–64,66–73,78] The plots show that there are statistically significant
improvements in WOMAC scores in all arms of all treatment groups across the follow-up
periods between two and twenty-four months. The pooled analysis was −37.69% change
[95% CI −50.30, −25.08, Q = 25.85, p < 0.0001] post two month treatment, −41.84% [95% CI
−53.52, −30.17, Q = 200.89, p < 0.0001] post three month treatment, −40.07% [95% CI
−54.44, −39.65, Q = 273.47, p < 0.0001] post six month treatment, −58.44% [95% CI −66.41,
−50.47, Q = 85.71, p < 0.0001] post twelve month treatment, −65.69% [−80.05, −51.32,
Q = 5.26, p = 0.022] post eighteen month treatment and −62.11% [95% CI −72.68, −51.54,
Q = 93.51, p < 0.0001] post twenty-four month treatment.
A forest plot was created to show a summary of the pooled analyses for the respective
follow-up times (Figure 3).
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Figure 3. Forest plot showing pooled analyses of percentage changes in WOMAC scores across the different follow-up
times (CI = confidence intervals, df = degrees of freedom, N = number, RE = random effects, Tx = treatment group).
Figure 3 shows the pooled analyses for all the follow-up time periods. In every follow-
up, post-treatment, there was an improvement in WOMAC scores. This improvement
increased as time went on, between less than month and up to 18 months post-treatment.
There was a slight reduction in improvement at 24 months, compared to 18 months. These
analyses were further pooled showing −48.02% [−59.16, −36.88, Q = 34.33, p < 0.0001].
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This suggests that overall, there was a statistically significant improvement in WOMAC
scores post treatment.
3.1. Classification of Osteoarthritis
Most studies in the literature used the Kellgren-Lawrence (KL) radiological classifica-
tion of osteoarthritis to grade the severity of OA in patients [48,49,62–64,66–71,73–75,78].
Due to the subjective nature of clinical diagnoses of OA, this was not used in any stud-
ies. Several of the included studies used this classification in their inclusion and ex-
clusion criteria where for example, patients with a KL grade of one would not be in-
cluded [48,49,63,64,66–69,71,72,75,78] in the study. Some studies also only included pa-
tients who had an average pain intensity of four or more on the 10-point visual analogue
scale for at least four months [48,63,64,70]. One study used the IKDC classification to grade
OA [65] and another used the Brandt Radiographic Grading Scale for Osteoarthritis [77].
3.2. Follow-Up
The most common follow-up period was 6.5 months [63,64,72,74]. Three studies had
a follow-up of 12 months [69–71]. Three studies had a follow-up of 24 months [38,60,61].
One study had a follow-up of one month [68]. Five studies had a follow-up between 12 and
24 months [49,65,67,73,74]. Two studies had a follow-up greater than 24 months [62,66].
3.3. Adverse Events
Only two studies have been found which did not report whether adverse events
(AEs) or severe adverse events (SAEs) occurred during the clinical study [65,78] The
rest of the studies all reported AEs. Two studies observed no AEs or SAEs during the
study [67,71]. One of these studies however had four cases of complications which were
deemed unrelated to the treatment regimen. These complications were high blood pressure,
chest pain, dyspnoea, and urinary retention [67]. Eleven studies reported that subjects
commonly experienced either transient pain or swelling of the joint after injection of the
AMSCs or SVF [48,49,64–70,72–74,77]. In most patients this resolved spontaneously. In
some patients, paracetamol was administered after which this resolved. Some studies also
reported that subjects experienced discomfort at the site of lipoharvest [49,68,74]. However,
this was resolved on further follow-up. Three studies reported patients experienced internal
haematomas at the site of lipoharvest [49,74]. Four studies reported SAEs [49,63–66,72].
One subject in one study had a urinary stone. The subject had a past medical history of
stones, and this was subsequently treated [63]. In another study, a subject experienced
angina pectoris. However, they had risk factors of hypertension and hyperlipidaemia which
predisposed them to the condition. In the remaining two studies, two patients and one
patient respectively experienced severe pain and swelling following the procedure [49,66].
The two patients recovered after four weeks, while the single patient recovered after
two weeks.
3.4. Outcome Measures
Several studies recorded two primary outcomes: clinical and radiological outcomes.
Studies utilised patient reported outcome measures (PROMs) to document clinical out-
comes and the PROMs used varied greatly between studies (Tables 4 and 5). The most
widely employed scoring systems were the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC), and the visual analogue scale (VAS). The former was used
by fifteen studies, while the latter was used by fourteen studies. The Knee Injury and
Osteoarthritis Outcome Score (KOOS) was used by six studies. The Knee Society Score
(KSS) was used by three studies. The Lysholm score was also employed by three studies.
The Numeric Pain Rating Scale (NPRS), range of motion (ROM) and bone marrow oedema
(BME) scoring were utilized by two studies. The Short Form-36 (SF-36), Hospital for Special
Surgery Knee score (HSS), Patient Global Assessment score (PGA), Short Arthritis Assess-
ment scale (SAS), International Knee Society (IKS) score, Japanese Knee Osteoarthritis
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Measure (JKOM), Joint Motion Amplitude (JMA) and the six minute walking distance
score (6MWD) were each utilized by one study.
Fewer papers assessed radiological outcomes. Six studies used radiographs to assess
KL grades of patients after the said treatment was given. Several studies utilised Magnetic
Resonance Imaging (MRI) to assess cartilage defects in the knee of patients. However, only
seven of these used standardised radiological scoring systems. Freitag et al., (2019) used the
MRI Osteoarthritis Knee Score (MOAKs). Koh et al., (2013) utilised the Whole-Organ MRI
Score (WORMS) [66]. Spasovski et al. (2018) used the 2D Magnetic Resonance Observation
of Cartilage Repair Tissue (MOCART) score [65]. Hong et al., (2019) used both WORMS
and MOCART [70]. Nguyen et al., (2016), Garza et al., (2020) and Tran et al., (2019), all
used the Outerbridge Classification System (OS) [67,69,78].
Only two studies conducted a second look arthroscopy and subsequent histological
analysis of the cartilage. Jo et al., (2014) used the International Cartilage Repair Society
(ICRS) score for histological grading [63], while Pers et al. (2016) used Osteoarthritis
Research Society International (OARSI) for histological grading [72].
4. Discussion
End-stage knee OA is currently managed with joint replacement surgery. This, how-
ever, does not target the underlying disease process of OA, but rather the end stage symp-
toms. Treatment options such as cartilage repair and osteotomy can delay the progression
of OA, but do not modify the disease [79,80]. Recently, use of AMSCs has sprung into the
clinical purview. AMSCs have the potential to regenerate new healthy articular cartilage
and thus alleviate the symptoms of knee OA. The results of this systematic review and
meta-analysis demonstrate that use of both AMSC and SVF treatments significantly reduce
WOMAC pain scores. This suggests that these treatments provide improved function and
a reduction in pain.
Numerous advantages of AMSCs have been described in the literature [76,81]. How-
ever, despite this, there is limited information on this topic in the literature, especially with
regards to human studies. Animal studies are more widespread since the safety of use of
AMSCs had to first be established, this was first conducted in mice. ter Huurne et al. (2012)
conducted such a study (C57BL/6 mice), with early-stage collagenase induced OA. They
found that injection of AMSCs into the knee joints of these mice, led to a reduction and
inhibition of cartilage destruction and formation of enthesophytes. In addition, there was
reduced synovial thickening and the treatments were safe.
Use of mice studies, have allowed the evaluation of safety of AMSC transplantation
to treat knee OA. Song et al., (2018) conducted a human clinical trial using adipose tissue
derived stem cells. However, they first conducted preclinical safety tests in vitro and
on BALB/c-nu nude mice. After confirming the safety of administering AMSCs isolated
through their methodologies, they enrolled 18 patients in their clinical study. These patients
were separated into three groups: low-dose (1 × 107), mid-dose (2 × 107), and high-dose
(3 × 107). Each patient was injected three times and followed up over a course of 96 weeks.
They found that use of AMSCs is safe for human use.
This study and several others documented AEs and SAEs. However, despite these
occurrences, they did not cause long term detriments to the patients’ quality of life and in
most cases spontaneously resolved. As such several studies deemed AMSC therapy to be
safe [48,49,63,65,72–74].
AMSC or SVF post treatment outcomes were determined by changes in WOMAC
scores in fourteen of the eighteen studies included in this systematic review. One study
conducted by Bansal et al. (2017) also used WOMAC scores, however since standard
deviation or error figures were not provided, this was excluded from quantitative meta-
analysis [77].
In the main pooled analysis, it was demonstrated that use of AMSCs and SVF in knee
osteoarthritic joints improved WOMAC scores. All studies that documented WOMAC
scores between two months and 24 months after treatment found that there was a sta-
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tistically significant improvement in WOMAC scores after treatment. This was the case,
regardless of the dose of AMSC or SVF used, or number of injections administered, sug-
gesting that the less laborious preparation of SVF compared to MSCs may be an advantage
as both therapies achieve good clinical outcomes. Furthermore, the pooled analyses in
Figure 3 illustrates that there is a statistically significant improvement in WOMAC scores
across all follow-up times, suggesting disease modification that persists and long-term
efficacy without the need for repeat administration of treatment. These improvements in-
creased as time from initial treatment increased between less than one month and eighteen
months post treatment. After this, at twenty-four months there was a slight decrease in
improvements in WOMAC scores. Overall, this suggests that the therapies act beyond
short-term analgesia, and lead to changes in the disease process. Improvements in these
scores suggest that these AMSC and SVF treatments reduce pain and improve knee func-
tion in patients with knee OA. Due to the low number of studies that compared AMSC
and SVF therapies, we were unable to conduct a meta-analysis to directly compare these
therapies. As there were also significant heterogeneity in the studies, subgroup analyses of
AMSC and SVF separately could not be conducted to yield meaningful results. The pooled
analysis in this review offers findings that are generalizable to multiple adipose derived
cell-based therapies.
Out of the eighteen studies included in this review, five investigated the effects
dose of AMSCs, had on outcomes [48,62,63,72]. In four of the studies, patients were
divided into three groups: a low dose group, medium dose group and high dose group.
Three of these studies found that patients in the high dose group gained greater clinical
improvements than those in the low and medium dose groups. This suggests that there
is a relationship between the number of AMSCs administered and the therapeutic effect
gained. This seems intuitive, as joint-native MSCs in OA patients may have diminished
capacity to proliferate and repair cartilage [82]. Thus, provision of healthy, functional
MSCs could prevent further cartilage loss and repair existing defects. This is in line
with conclusions made by two studies which investigated radiological outcomes. They
discovered greatest reduction in cartilage defects were found in the high dose groups [62,63].
One can posit that this suggests that increasing dose is correlated with greater regenerative
potential. Conclusions drawn by Pers et al., (2016) differed with the aforementioned
studies, finding that the lowest dose group had the best improvements in clinical outcomes.
This may have arisen, since the authors documented that the patients with the highest
levels of inflammation were those in the low dose group [72]. AMSCs could have been
primed to exert their immunoregulatory functions more efficiently in this more prominent
inflammatory background. However other studies in the literature show similar findings,
implying that lower dose administration of AMSCs may be more effective than high
dose [83,84]. If low doses of AMSCs, are just as or more effective than high doses, then
clinical and radiological improvements do not correlate with the number of cells used.
Using less cells may reduce the laborious preparation required. Moreover, this may cut
down on costs, making AMSCs more appealing for clinical use. Since very few studies
investigated doses on outcomes, subgroup analyses were not conducted.
Freitag et al., (2019) compared the effect one injection of 100 × 106 cells, to two
injections of 100 × 106 cells. Both were compared to a control group. They concluded that
two injections of AMSCs achieved more consistent OA stabilisation than one injection [49].
They were the only study to do this, which represents a gap in the literature. This indicates
that multiple low dose injections of AMSCs may provide superior clinical and radiological
improvements than a singular dose. These results may be reflective of the overall increased
number of cells used in the double injection group. On the other hand, this increased
efficacy of the double injection treatment could be due to spaced out exposure to AMSCs.
Repetitive low dose spaced out injections of AMSCs may prove to be more successful
than a single large dose injection. Nevertheless, there is also a possibility that there is a
ceiling on the correlation between numbers of injections and improvements seen. Moreover,
Freitag et al., (2019) reported an increase in the number of moderate AEs in the second
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injection group. This implies that increased numbers of injections are linked to increased
AEs, which may affect the tolerate of the therapy in question.
Yakota et al. (2019) was the only study that compared the efficacy of AMSCs with
SVF [74]. They found that both therapies improved osteoarthritic symptoms and pain.
However, when they analysed the clinical scores, they found that the improvements were
more significant and occurred earlier in the AMSC group. Earlier clinical improvements
suggest that AMSCs have a faster mechanism of action. More significant clinical improve-
ments suggest that AMSCs are superior to SVF for symptomatic control of knee OA. No
radiological outcomes were investigated in this study. Therefore, no conclusions can be
drawn regarding the cartilage regenerative potential of either treatment. However, other
studies have shown that AMSCs have great cartilage regenerative potentials, and reduce
cartilage defects [62,63]. Yakota et al., (2019) also discovered that there was a higher fre-
quency of knee effusion and minor complications related to the harvesting of adipose tissue
in the SVF patient group [74]. As such iatrogenic complications may be higher in SVF. This
may affect tolerate and favourability of such treatment in the future. More clinical studies
need to be conducted to make robust conclusions regarding which treatment is superior.
Garza et al., (2020) was the only study to compare the effects of different doses of SVF
on clinical and radiological outcomes. They led a study in which they compared a placebo
group using hyaluronic acid, with a low dose SVF group (1.5 × 107 cells) and a high dose
SVF group (3.0 × 107 cells) [69]. They discovered both doses of SVF resulted in improved
WOMAC scores compared to the placebo. Nevertheless, there was no statistical difference
between the high and low dose groups. Therefore, this suggests that the benefits expressed
by SVF is not dose dependent. Additionally, there was no visible quantifiable changes
detected in cartilage thickness on the MRI scans between all three groups. The result from
the radiological outcomes suggests that unlike AMSCs, which improve cartilage defects,
SVF do not. Therefore, SVF treatment has no impact on the disease process of OA and
only plays a role in symptomatic relief. This could be potentially explained by the fact
that AMSCs have a higher number of colony forming fibroblast units (CFU-F) and greater
differentiation potential [58]. This study also further illustrates the limitations of hyaluronic
acid for the treatment of knee OA. This review has found a gap in the literature, which
must be addressed with studies investigated SVF dose and outcomes, to further determine
the role of SVF therapy in the treatment of knee OA.
Koh et al., (2013), Bansal et al. (2017) and Nyugen et al. (2016) were the only studies
which used a growth factor alongside SVF [66,67,77]. They all used a platelet rich plasma
(PRP) scaffold. All studies concluded that there was significant improvement in clinical
scores long term post treatment. Use of PRP may have improved the efficacy of treatments.
PRP is known to enhance MSC proliferation and chondrocyte differentiation, and as such
could bolster cartilage degeneration [85,86]. However, none of these studies compared use
of PRP alone against SVF and PRP. As such the efficacy of PRP cannot be quantified. Only
with further studies, comparing AMSCs and SVF with and without PRP can we definitively
determine the role of PRP in therapy for knee OA. If use of growth factor proves to increase
efficacy, these could be applied to AMSC therapy as well.
Many of the studies included in this systematic review used K-L grading of OA
as an inclusion and exclusion criterion in the recruitment of their patients. Out of all
studies, only one included patients with a K-L grade of 1 [73]. As such most of the studies
could not determine the efficacy of treatments on low grade knee OA. Since, there is
reduced levels of inflammation in the earlier stages of OA than end stages, AMSC and
SVF therapy may be more effective. Alternatively, these therapies may be more effective in
end stage OA, since the high inflammatory environment could modulate cells to exercise
their immunoregulatory function more effectively. In addition, only eight studies included
patients with K-L grade 4 [48,62–64,68,71,72,74]. As such there is less data on the effects
of AMSC treatment on end stage severe knee OA, and more on middle stage knee OA.
Furthermore, most studies did not stratify patients according to the severity of the OA. As
such they could not determine whether the severity of knee OA has any bearing on the
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efficacy of the MSC treatment. Nonetheless, three of the studies did make observations
based on this. Tran et al., (2019) inferred that treatment was more effective in patients
with KL grade 3 than with grade 2 [78]. In the higher severities of OA, there is greater
inflammation. On the other hand, Nyugen et al., (2016) and Yokota et al., (2019) found that
lower K-L grades had greater clinical improvements, indicating that efficacy was greater in
patients with less severe OA [67,74]. If this is the case, more studies need to be conducted
to include K-L grade 1 patients.
In addition to K-L grading, studies did not stratify patient cohorts according to age
or BMI. Thus, the impact these could have on the efficacy of outcomes is unknown. It is
possible that in younger patients, who have superior regenerative potential, the quality and
therefore efficacy of AMSC and SVF is superior to elderly patients [87]. Maredziak et al.
(2016) illustrated that there is reduced CFU-F, proliferation rates, and quantified chondro-
genic and osteogenic differentiation in aged AMSC cells. Furthermore, aged cells seem to
shift more in favour of adipogenic differentiation [88]. In addition, it has been shown that
there is a biological role of adipose inflammation in obese patients and OA [89]. As such, it
is possible, this mechanism of OA may respond differently to AMSC and SVF treatments,
compared to age related articular cartilage degeneration. Therefore, stratifying patients
into different BMI groups, may be of benefit. However, this must be investigated further
before definitive conclusions can be made.
The gold standard of evaluating new-born cartilage in the face of cartilage repair, is
second look arthroscopy and histological biopsy. It is important to determine quantify
the size of cartilage regeneration as well as the constitution of the cartilage. Nevertheless,
only two studies performed such procedures [63,72]. To confidently determine the role of
AMSC treatment in knee OA, we must understand the qualities and mechanism of cartilage
repair involved.
Out of all the studies, six used arthroscopies prior to injection of the treatment.
Roata et al. (2019) and Jo et al., (2017) only used arthroscopy as guidance for injection of
the AMSCs into the osteoarthritic site [62,73]. However, the rest of the studies performed
arthroscopic debridement prior to injection of the treatment [67,70,74]. As such it is possible
that this led to bias of outcome. Due to the heterogeneity in treatment modality between
the studies, and the low number of studies that examined arthroscopic delivery, sub-group
analysis was not conducted. It should be noted that arthroscopy for the treatment of knee
OA has been shown to be largely ineffective [90,91]. However, arthroscopic debridement
removes inflammatory synovial fluid which can interfere with AMSC adhesion in vitro,
and therefore increasing the effectiveness of said treatment [73]. As such, arthroscopic
debridement may prime the joint to become more responsive to injections. Consequently,
one cannot definitively rule out the effect arthroscopy has on the clinical and radiological
outcomes of AMSC treatment.
Five of the studies included, utilised ultrasound to aid guidance of the AMSC or
SVF injections. When the outcomes of these studies are compared to those which used
arthroscopy or utilised neither, there is no difference in clinical outcomes. As mentioned
previously, only two studies conducted second look arthroscopies. Hence, we cannot
determine whether use of image guidance leads to greater cartilage regeneration. Future
studies should directly compare use of image guidance against blind injection. In addition,
studies should perform radiological and histological analysis on all patients to determine
if imaging guidance has any bearing on cartilage regeneration.
There was a lack of long-term studies carried out, as shown in the results. The
average follow-up across all studies was 60.1 weeks. The longest follow-up period was
104 weeks [62]. This would be considered a short-term follow-up. Thus, there is a gap
in the literature for such long-term studies. As a result, the effect AMSC injections and
SVF injections have on long term knee OA is unknown. The importance of this was made
evident by Park et al., (2016). They conducted a study in which they investigated cartilage
regeneration in OA patients, through use of umbilical cord derived MSCs. They discovered
that three years after treatment, cartilage repairs persisted. This implied that use of such
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MSCs could provide a long-term solution to OA. Conversely, Jo et al., (2017) found that
two years post treatment, cartilage deterioration was apparent. As such, it is possible that
the effect of AMSC and SVF treatment may be limiting, and further injections may be
required for persistence of cartilage regeneration. Alternatively, it could be possible after
several years, the knee joint becomes unresponsive to AMSC and SVF treatment injections.
Only with long term studies, can the lasting implications of this treatment be determined.
Understandably, the studies included in this review are very recent, as such long-term
studies with 5–10-year follow-ups are not possible at this stage.
There are significant variations in the outcome measures utilised by studies. In
terms of clinical outcomes, most studies using WOMAC and VAS. However, several did
not. As a result, the clinical outcomes recorded are harder to compare between studies.
Scoring systems such as WOMAC and VAS are non-specific. Perhaps creation of a PROM
specifically for post intra-articular injection would be more beneficial. Use of a handful of
scoring systems rather than a wide array may allow for better comparison between studies
and therefore allow scientists to determine what the most effective treatment for knee OA.
SVF can be prepared through various methods. It has been shown that different
methods have different compositions and properties [92]. This has not been addressed by
any of the studies included in this review which investigated SVF. As a result, it may be
unwise and inaccurate to compare the results of studies which used differing methods to
produce their SVF.
The gold standard in medical research when testing the efficacy of a new treatment
is a double blinded randomised controlled trial (RCT). However, use of AMSCs is very
novel. Many of the studies included in this systematic review were carried out as pilot
studies. Out of these studies, only six used a control group [49,64,67,69,70,78] As such the
other studies are unable to truly define the efficacy of the treatments tested. Many of these
studies recognised this, however their principal goal was to determine the safety of AMSCs
rather than its effectiveness. They stated that future studies should include control arms in
clinical trials. However, Freitag et al., (2019) and Pers et al., (2016) believed there may be
ethical concerns with conducting an RCT [48–78]. All patients would have to undergo a
lipoharvest procedure before randomisation. This procedure is not without complications.
A study conducted by Comella et al. (2017) found that such complications are low in
lipoharvest procedures [93]. Since these studies were pilot in nature, their sample sizes
were also very small, with the largest being 80 patients, and the average being 30.5 across
all studies.
5. Conclusions
The studies in this systematic review have established the safety and efficacy of both
AMSC therapy and SVF therapy for knee OA in humans. In addition, the meta-analyses
show that use of AMSC and SVF therapy for knee OA definitively improves WOMAC
scores up to two-years, with improvements increasing with time. This suggest that AMSC
and SVF treatments reduce pain and improve knee function in patients with severe knee
OA. Future clinical studies must now incorporate control arms and have larger sample
sizes to successfully determine the effectiveness of these treatments. Specifically, there
is little to no literature on studies comparing use of single vs multiple AMSC injections,
comparing AMSC treatments with SVF treatments and the effect of different doses of SVF
on outcomes.
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Appendix A
Databases searched:
OVID MEDLINE®: 1946 TO JUNE WEEK 4 2020
Date of search: 29/06/20
Date range searched: January 1946 to June 2020
SEARCH STRATEGY
1. exp cartilage/ or exp “bone and bones”/
2. exp Injections, Intra-Articular/
3. exp Osteoarthritis, Hip/ or exp Osteoarthritis/ or exp Osteoarthritis, Spine/ or exp
Osteoarthritis, Knee/
4. exp Mesenchymal Stem Cells/ or exp Mesenchymal Stem Cell Transplantation/
5. exp Transplantation, Homologous/ or exp Stem Cell Transplantation/ or exp Trans-
plantation, Autologous/ or exp Mesenchymal Stem Cell Transplantation/




10. 4 or 5 or 8 or 9
11. 1 or 2 or 10
12. 6 or 7
13. 11 and 12
14. 3 and 13
15. Limit 14 to (English language and humans)
EMBASE: 1974 TO 2019 JUNE 26
Date of search: 29/06/20
Date range searched: January 1974 to June 2019
SEARCH STRATEGY
1. exp cartilage/
2. exp intraarticular drug administration/
3. exp knee osteoarthritis/
4. exp mesenchymal stem cell transplantation/ or exp mesenchymal stem cell/
5. exp autograft/
6. exp adipose tissue/
7. adipo*.tw.
8. 4 or 5
9. 1 or 2 or 8
10. 6 or 7
11. 9 and 10
12. 3 and 11
13. Limit 12 to (human and English language)
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COCHRANE LIBRARY: 1946 TO JUNE 2020
Date of search: 29/06/20
Date range searched: January 1946 to June 2020
SEARCH STRATEGY
#1 MeSH descriptor: [Cartilage] explode all trees
#2 MeSH descriptor: [Injections] explode all trees
#3 MeSH descriptor: [Osteoarthritis] explode all trees
#4 MeSH descriptor: [Mesenchymal Stem Cells] explode all trees
#5 MeSH descriptor: [Stem Cells] explode all trees
#6 MeSH descriptor: [Adipose Tissue] explode all trees
#7 MeSH descriptor: [Autografts] in all MeSH products
#8 MeSH descriptor: [Heterografts] in all MeSH products
#9 #1 or #2 or #3
#10 #4 or #5 or #6 or #7 or #8
#11 #10 and #9
#12 #11 and #6
WEB OF SCIENCE: 1900 TO 2020
Date of search: 29/06/20
Date range searched: 1900 to June 2020
SEARCH STRATEGY
#1: (TS = (cartilage or inject*)) Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
#2: (TS=(osteoarthritis)) Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
#3: (TS=(mesenchymal stem cell or stem cell or homologous or autologous or autograft
or heterograft)) Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
#4: (TS=(adipose)) Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
#5: #3 or #1 Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
#6: #5 and #2 Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
#7: #6 and #4 Indexes=SCI-EXPANDED, CPCI-S Timespan=1900–2020
CLINICAL TRIALS.GOV: 1900 TO 2020
Date of search: 29/06/20
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